Osteoporotic fractures may impair life as much as the complications of diabetes.

RATIONALE, AIMS, AND OBJECTIVES: To compare the effect of osteoporotic fractures and complications of diabetes mellitus on quality of life (QoL). METHOD: A cross-sectional study was performed in 840 patients with osteoporosis and in 943 patients with diabetes in Hungary to estimate the effect of osteoporotic fractures and microvascular and macrovascular complications of diabetes on QoL using the EQ-5D questionnaire. Ordinary least-squares regression was performed for the analysis to control for age and gender. RESULTS: The effects of certain of osteoporotic fractures and diabetes complications were similar in size measured by the EQ-5D. Patients with hip fractures and compressions of the vertebrae suffered more than 0.2 drop in their QoL, which is comparable in size to the most severe complications of diabetes, such as vision loss and amputations. CONCLUSIONS: The use of mortality and premature mortality as the traditional measures of disease burden in public health policy making means that diseases which strongly affect QoL but less survival might not get the necessary priority. This is especially the case in low-income and middle-income countries where studies on QoL are scarce. Our comparative analysis, which showed that osteoporotic fractures reduce QoL as much as major complications of diabetes, highlights the need for comprehensive disease burden assessment, including losses in functionality and QoL, to support decision making.

[Assessment of risk factors for fractures in postmenopausal women with osteoporosis]. / A csonttörés kockázati tényezoinek vizsgálata postmenopausás, osteoporosisos nobetegek körében.

INTRODUCTION: The main consequence of osteoporosis is bone fracture. Bone fracture risk is determined by several risk factors beyond osteodensitometric results. Some of these factors could be estimated by simple clinical questionnaires. AIM: The aim of the present study (Score-HU) was to investigate the risk factors of bone fracture among osteoporotic postmenopausal women (n = 11,221), who were examined in an osteologic outpatient departments. METHOD: Risk factors of each patient were recorded with the use of a simple identical data sheet. RESULTS: The incidence of risk factors were the following: previous bone fracture (79.4%), medication (except antiporotic treatment, antihypertensive drugs 67.9%, sleeping pills 36%, antidepressants 26.5%, corticosteroids 13.5%), decreased mobility (44.6%), early menopause (31.9%), smoking (31.2%), frequent falls (29.1%), and poor health status (more than 3 chronic diseases; 24.1%). CONCLUSIONS: Estimating the above mentioned risk factors we could assess the bone fracture risk more accurately than taking alone the bone mineral density results into consideration.

Increased bone fracture prevalence in postmenopausal women suffering from pollen-allergy.

INTRODUCTION: Our aim was to investigate whether pollen-allergy can affect bone mass and fractures in postmenopausal women. METHODS: A total of 125 postmenopausal pollen-allergic women (mean age: 61.26 yr) were split into four groups: (1) treated with neither H1 histamine receptor (H1R) antagonist nor inhaled corticosteroid (n=43); (2) treated only with H1R antagonist (n=53); (3) treated with both H1R antagonist and inhaled corticosteroid (n=17); (4) treated with only inhaled corticosteroid (n=12). Treatment, in the appropriate groups, had occurred for at least 5 years, seasonally. One-hundred non-allergic postmenopausal subjects matched for age, body mass index (BMI), and age at menopause served as controls. RESULTS: Overweight and obesity (25 kg/m(2) < or =BMI) were common among the allergic women (76%). Allergic patients without treatment had a slightly lower bone density than their non-allergic counterparts. The rate (34.9%) of prevalent low-energy fractures (distal forearm, hip, and clinical vertebral fractures) in untreated allergic patients was almost triple that observed in non-allergic women (13%, chi(2) p=0.003). Bone fracture occurred more often in H1R-only treated patients (30.19%) than in controls (chi(2) p=0.01); however, clinical vertebral or hip fractures developed neither in those treated only with H1R antagonist nor in those who received both H1R antagonist and inhaled corticosteroid. Bone fractures were more frequent among patients with inhaled steroid treatment than among patients with a combined treatment of inhaled steroid and antihistamine (50 versus 29.4%). BMI predicted prevalent fractures at 1.278 (95% CI: 1.047-1.559, p=0.016) for a 1 kg/m(2) increase among untreated allergic patients. CONCLUSION: In conclusion, we found a high prevalence of low-energy fractures among pollen-allergic postmenopausal women which was associated with obesity. It is possible that the H1R antagonists compensate for both the negative effect of pollen-allergy and the adverse effect of inhaled corticosteroid treatment on bone fracture risk.

[Up-to-date treatments for osteoporosis]. / Az osteoporosis korszeru kezelése.

Osteoporosis, despite effective treatment, has a great significance world-wide. It is possible to avoid developing a serious osteoporosis and having bone fracture if we realise the problem at the proper time and take the risk factors into consideration. This article summarises the medications currently used in osteoporosis treatment. The assignment of drugs was by the primary effect on bone metabolism, accordingly anti-catabolic or anabolic drugs. We emphasise the difference between the enlargement of bone mass and the improvement of bone quality and the problem which occurs when we take no notice of this difference. This recognition challenges developing new drugs.